About 200 reports

Fig ## PARADIGM SHIFT: RX TO CDX Fig ## ## ## ## ## ## ## ADVANCEMENTINTHERAPYAREAS ANALYSIS Sense and Response Predict and Act?

  • Autoimmune Disease
  • North America
  • United States
  • World
  • Market Size

EXECUTIVE SUMMARY ##.

  • Autoimmune Disease
  • Pathology
  • APAC
  • World
  • Market Shares

Middle East & Africa ##.

  • Autoimmune Disease
  • World
  • Market Size
  • bioMerieux S.A.
  • Roche Group
  • 2.2 Symptoms

They form a protein-RNA complex called RNA-induced silencing complex (RISC) which causes the siRNA to unwind, and the complementary functional strand is loaded into RISC.

  • Autoimmune Disease
  • AbbVie Inc.
  • Amryt Pharma plc
  • Celgene Corporation
  • Fibrocell Science, Inc.

ELSEVIER; ##-##.

  • Autoimmune Disease
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • Remicade group

TABLE ##. ##.

  • Autoimmune Disease
  • World
  • Forecast
  • Market Size
  • MicroBiome Therapeutics LLC
  • Latest stage of development

## Alpha ## (Elongation Factor Tu or Eukaryotic Elongation Factor ## A ## or L k t R ##S Ribosomal RNA (##S rRNA) t Cl t M b ## EEF##A EEF##A##) minocycline BioPharmX Inc.

  • Autoimmune Disease
  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Apricus Biosciences, Inc.

Product name X e lja nz E nb re l Infle ctra Me d ro l A d a li muma b b i o si mi la r Generic name Molecular target JA K ## L ymp ho to xi n a lp ha ## ## ## ## B i o si mi la r TNF Inte rna l Route ## ## ## ## ## ## ## ## Oth e r co m p a n y re ve n u e Drug details Molecu

  • Autoimmune Disease
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Janssen Biotech, Inc.
  • Johnson & Johnson
  • JOHNSON & JOHNSON

In January 2015, the company entered into a $## million RNA deal with Ionis Pharmaceuticals to develop autoimmune drugs.

  • Autoimmune Disease
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson & Johnson
  • Pfizer Inc.

In January 2015, it entered into an $## million RNA deal with Isis Pharmaceuticals to develop autoimmune drugs.

  • Autoimmune Disease
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.

Moderna Therapeutics Inc (Moderna Therapeutics) is a developer of messenger RNA therapeutics.

  • Autoimmune Disease
  • Cancer
  • Sweden
  • Karolinska Institutet Holding
  • Takeda Pharmaceutical Company Limited

Europe Autoimmune Disease Therapeutics Market (2019-2025) Europe Autoimmune Disease Therapeutics Market Chapter ##.

  • Autoimmune Disease
  • Pathology
  • Therapy
  • Europe
  • Market Size

SIX-THIO- IMP AND ##-THIO-GMP INHIBIT SYNTHESIS OF DNA, RNA, AND PROTEIN IN LYMPHOCYTES AND LEUKOCYTES.

  • Autoimmune Disease
  • Market Size
  • EA Pharma Co., Ltd.
  • Pfizer Inc.
  • Remicade group

In January 2015, it entered into an $## million RNA deal with Isis Pharmaceuticals to develop autoimmune drugs.

  • Autoimmune Disease
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • Merck & Co., Inc.

The company offers sample and assay technologies that are used to isolate RNA, DNA, and proteins from blood and tissue samples that contain biological materials.

  • Autoimmune Disease
  • World
  • Abbott Laboratories, Inc.
  • EUROIMMUN AG
  • Roche Group
  • 4.5.1.1 Drug Forecast

GED-## is designed to target the messenger RNA for Smad##, thereby reducing Smad## protein levels.

  • Autoimmune Disease
  • Market Size
  • AbbVie Inc.
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

Immunology and Allergy Clinics of North America; ##(##): ##- ## Lebwohl MG, et al. (2013).

  • Autoimmune Disease
  • Market Size
  • Amgen Inc.
  • Biologics, Inc.
  • Merck & Co., Inc.
  • DESCRIPTION OF PRODUCTS

It is eventually incorporated into ribonucleic acid (RNA), and inhibits deoxyribonucleic acid (DNA) formation by blocking thymidylate synthetase.

  • Autoimmune Disease
  • Allergan plc
  • Galderma S.A.
  • Pfizer Inc.
  • Valeant Pharmaceuticals International, Inc.

Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and doublestranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

He stressed, however, that the study was only a " testing ground" for potential future work with the small, non-coding RNAs.

  • Autoimmune Disease
  • Immunotherapy
  • United States
  • Product Initiative
  • Sirnaomics, Inc.
  • Target
  • CLINICAL TRIAL PROFILE SNAPSHOTS

Falk Pharma GmbH ## ## ## ## ## ## Allergan Plc ## ## ## ## ## ## Shire Plc ## ## ## ## ## ## Acorda Therapeutics Inc ## ## ## ## ## ## Celgene Corp ## ## ## ## ## ## ChemomAb Ltd ## ## ## ## ## ## ChemoCentryx Inc ## ## ## ##

  • Autoimmune Disease
  • Clinical Trial
  • Therapy
  • World
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • World
  • Product Initiative

In the combination arm, all patients had HDV RNA decline and ## were HDV RNA negative at week ##.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Intercept Pharmaceuticals, Inc.

Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its RNA-based companion diagnostic, next-generation sequencing (NGS) assay (Trailblaze Pharos).

  • Autoimmune Disease
  • Cancer
  • United States
  • Product Initiative
  • Loxo Oncology, Inc.

RNAi is a physiological phenomenon in which small, double-stranded RNA molecules (small interfering RNA, siRNA) reduce expression of homologous genes.

  • Autoimmune Disease
  • Healthcare
  • United States
  • World
  • Product Initiative

KCN-## acts by inhibiting hypoxia inducible factor ## alpha (HIF-## alpha) interaction.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Cerulean
  • ALOPECIA - PIPELINE BY OLIX PHARMACEUTICALS INC, H1 2019
  • ALOPECIA - PIPELINE BY LEE'S PHARMACEUTICAL HOLDINGS LTD, H1 2019

The therapeutic candidate is a small interfering RNA (siRNA) based on RNA interference (RNAi) technology.

  • Autoimmune Disease
  • Hair Growth
  • Pharmaceutical
  • United States
  • Product Initiative
  • Target
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Falk Pharma GmbH ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## PRA Health Sciences Inc ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## Gilead Sciences Inc ## ## ## ## ## ## CymaBay Therapeutics Inc ## ## ## ## ## ## Albireo Pharma Inc Source: Glo

  • Autoimmune Disease
  • Clinical Trial
  • Pharmaceutical
  • World
  • Product Initiative
  • PIPELINE BY GILEAD SCIENCES INC, H1 2018
  • PIPELINE BY IDERA PHARMACEUTICALS INC, H1 2018

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Autoimmune Disease
  • Immunotherapy
  • United States
  • Product Initiative
  • Idera Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • World
  • Product Initiative
  • Simbec Research Limited